Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
国: オーストリア
言語: 英語
ソース: HMA (Heads of Medicines Agencies)
製品の特徴
(SPC)
09-07-2013
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
buprenorphine hydrochloride 0.32 mg
から入手可能:
Animalcare Limited
ATCコード:
QN02AE01
医薬品形態:
Solution for injection
治療群:
buprenorphine
治療領域:
Cats, Dogs
承認日:
2008-02-15
製品の特徴
Revised: June 2013
AN. 00507/2012
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats (UK, BE, FR, IE, LU, NL,
ES)
Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each ampoule contains:
Buprenorphine 0.3 mg/ml as buprenorphine hydrochloride.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dog
Post-operative analgesia.
Potentiation of the sedative effects of centrally-acting agents.
Cat
Post-operative analgesia.
4.3 CONTRAINDICATIONS
The product should not be used pre-operatively for caesarean section (see Section 4.7).
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Revised: June 2013
AN. 00507/2012
Page 2 of 6
Buprenorphine may occasionally cause significant respiratory depression and, as with
other opioid drugs, care should be taken when treating animals with impaired
respiratory function or animals that are receiving drugs that can cause respiratory
depression.
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of ac
完全なドキュメントを読む
